Literature DB >> 21303916

Non-alcoholic fatty liver disease: what's new under the microscope?

Elizabeth M Brunt1.   

Abstract

Pathologist's observations have remained central to the evolution of the field of non-alcoholic fatty liver disease, even with the advent of increasingly effective non-invasive markers of advanced fibrosis. As the field matures, the role of pathology has also shifted from being largely descriptive to being confirmatory and diagnostic, as well as providing semi-quantitative evaluation of specific findings, particularly in therapeutic interventional trials. Some newly appreciated histopathological findings will be discussed in this review.

Entities:  

Mesh:

Year:  2011        PMID: 21303916     DOI: 10.1136/gut.2010.218214

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress.

Authors:  Tianhui Liu; Ping Wang; Min Cong; Xinyan Zhao; Dong Zhang; Hufeng Xu; Lin Liu; Jidong Jia; Hong You
Journal:  Br J Pharmacol       Date:  2018-10-23       Impact factor: 8.739

Review 2.  Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 3.  Pathogenesis of nonalcoholic steatohepatitis.

Authors:  Wensheng Liu; Robert D Baker; Tavleen Bhatia; Lixin Zhu; Susan S Baker
Journal:  Cell Mol Life Sci       Date:  2016-02-19       Impact factor: 9.261

4.  Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis.

Authors:  Andrew A Taitano; Michael Markow; Jon E Finan; Donald E Wheeler; John Paul Gonzalvo; Michel M Murr
Journal:  J Gastrointest Surg       Date:  2014-12-24       Impact factor: 3.452

5.  Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosis.

Authors:  Keisuke Kakisaka; Sophie C Cazanave; Christian D Fingas; Maria E Guicciardi; Steven F Bronk; Nathan W Werneburg; Justin L Mott; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-13       Impact factor: 4.052

6.  A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.

Authors:  Anuradha Krishnan; Tasduq Sheikh Abdullah; Taofic Mounajjed; Stella Hartono; Andrea McConico; Thomas White; Nathan LeBrasseur; Ian Lanza; Sreekumaran Nair; Gregory Gores; Michael Charlton
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-02-23       Impact factor: 4.052

7.  [Non-alcoholic steatohepatitis and cirrhosis in young adult patients with hypothalamic-pituitary dysfunction].

Authors:  D Goltz; K Schötta; H Zhou; H-P Fischer
Journal:  Pathologe       Date:  2013-07       Impact factor: 1.011

8.  Lipoprotein metabolism in nonalcoholic fatty liver disease.

Authors:  Zhenghui Gordon Jiang; Simon C Robson; Zemin Yao
Journal:  J Biomed Res       Date:  2012-12-01

Review 9.  Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.

Authors:  Howard C Masuoka; Naga Chalasani
Journal:  Ann N Y Acad Sci       Date:  2013-01-30       Impact factor: 5.691

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.